Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
CEL-SCI
company
About
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
- 11 - 50
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $4.40M
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 1983
- Number Of Employee
- 11 - 50
- Operating Status
- Active
CEL-SCI Corporation is a biotechnology company. CEL-SCI is involved in the research and development of immunotherapy products for the treatment of cancer and infectious diseases. The Company's core capabilities include: drug discovery, research, development and manufacturing of complex biological substances.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$4.40M
CEL-SCI has raised a total of
$4.40M
in funding over 2 rounds. Their latest funding was raised on
Aug 20, 2009 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 20, 2009 | Post-IPO Equity | $4.40M | 2 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
CEL-SCI is funded by 2 investors.
Rockmore Capital
and Midsummer Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Rockmore Capital
|
— | Post-IPO Equity |
Midsummer Capital
|
— | Post-IPO Equity |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
